Hyderabad,
AP,
India
(PRBD.net)
9/7/2010 12:00:00 AM
-
In 2009, the global hepatitis market was estimated to be worth $3,276m, representing a Compound Annual Growth Rate (CAGR) of 3.1% between 2001 and 2009. By 2016, the global hepatitis market is estimated to reach $5,977m, indicating a CAGR of 9% between 2009 and 2016.
The hepatitis A and hepatitis C markets are expected to grow at a high rate during the forecast period. The hepatitis B market alone is expects to witness a low growth.
The target patient base of the hepatitis market includes newly infected or diagnosed hepatitis patients, the treatment of non-responders and patients who discontinued treatment. Hence, there is a huge unmet need in the market. Also, the high cost of therapy has been a major concern for hepatitis patients. Except for antivirals such as Ribavirin, all treatment therapeutics for hepatitis are biologics. The fact that cost of therapy for biologics is high; the annual cost of therapy for hepatitis is high as well.
For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=The-Hepatitis-Therapeutics-Market-to-2016-Strong-Hepatits-C-Vaccine-Pipeline-and-Cost-Effective-Treatments-will-Drive-the-Global-Hepatitis-Market&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
The hepatitis pipeline portfolio has 208 molecules across the different developmental stages. The number of programs in the regulatory filing, Phase III and Phase II stages of development accounted for approximately 77% of the total number of pipeline programs. In addition, the pipelines for hepatitis B and hepatitis C contain 97% of the total pipeline molecules. This indicates that the launch of these drugs will boost the hepatitis market.
The hepatitis C therapeutics pipeline has four molecules in Phase III. There are various promising molecules in the clinical development pipeline for the treatment of hepatitis C. The introduction of novel therapies will be a driver for the market. For example, products like boceprevir, zalbin, telaprevir, and RG7128 are already in the clinical development stage. The launch of these molecules will again support market growth.
The hepatitis B pipeline has 10 molecules in the Phase III stage, but most of them are combination therapies. The Phase II stage is also dominated by combination therapies. The pipeline for hepatitis is lacking in novelty and hence it is weak. The pipeline portfolio for hepatitis A is also weak, with six programs in the different developmental stages. The fact that the hepatitis C therapeutics market is expected to witness a high growth during the forecast period will support the global hepatitis market as a whole.
GBI Research, the leading business intelligence provider, has released its latest research, “Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Vaccine Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market”. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global hepatitis therapeutic market. The report analyzes the markets for hepatitis in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=The-Hepatitis-Therapeutics-Market-to-2016-Strong-Hepatits-C-Vaccine-Pipeline-and-Cost-Effective-Treatments-will-Drive-the-Global-Hepatitis-Market&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
|
|
|
|
Contact Information
Rajesh Gunnam
GlobalData
e-park, hyderabad
Hyderabad,
AP,
500050
India
91-40661-66782
rgunnam@globaldata.com
Visit Our Site
|
Get your Press release distributed to 90+ PR directories and 100’s of Journalists.
FREE featured news at PRBD.NET, PR4links.com and Sardnews.org worth $27.
|
|
|
|